Our purpose is to reimagine medicine to improve and extend people's lives.

Scientist working in a lab

Our vision is to become the most valued and trusted medicines company in the world.

Scientist working on a computer

Our strategy is to deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

 

Focus Areas

To support this strategy, we have clear focus areas and priorities to create value for our company, our shareholders and society.

Therapeutic areas

Strategy - Cardiovascular

Heart icon

Cardiovascular disease (CVD), which includes chronic conditions affecting the heart and blood vessels such as heart failure, heart attacks and strokes, is the world's leading cause of death and one of society's biggest health concerns.

Strategy - Immunology

Antibody icon

Immunology covers a broad spectrum of conditions, including chronic skin diseases such as psoriasis and hidradenitis suppurativa. Autoimmune conditions alone, which form a small part of immunological diseases, affect an estimated 4.5% of the world’s population and their prevalence is increasing.

Strategy - Neuroscience

Brain icon

Around 2 million people worldwide suffer from multiple sclerosis (MS), an autoimmune disease that is the most common cause of neurological disability unrelated to trauma in people under 40 years of age.

Strategy - Solid tumors

Lymphocyte icon

Cancer is the second leading cause of death worldwide. The World Health Organization (WHO) estimates there will be 50% more new cancer cases in 2040 than there are today. At Novartis, we’re committed to unraveling the inner workings of cancer. We’re developing new therapies for a range of common and rare cancers, investing in diverse technology platforms and experimenting with combination approaches.

Strategy - Hematology

Red blood icon

Hematology encompasses both malignant cancers and non-malignant disorders of the blood and blood components, such as blood cells and bone marrow cells. There are many different causes of these cancers and disorders, and prognosis can vary significantly among the different illnesses.

Technology platforms

Strategy - xRNA

DNA helix icon

RNA therapies use various forms of ribonucleic acids (RNA) to modify biological pathways in the body to treat or cure specific illnesses.

Strategy - Radioligand

Hub diagram icon

Radioligand therapy delivers precision-targeted radiation to cancer cells in the body with the goal of limiting damage to surrounding tissue.

Strategy - Gene & Cell therapy

Gene icon

Gene therapies modify part of a patient’s genetic makeup to help treat genetic or inherited diseases. Cell therapies treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body.

Strategic Priorities

These focus areas are supported by strategic priorities, which determine how we implement our strategy.

Deliver high-value medicines

to accelerate growth.

Embed operational excellence

to deliver returns.

Strengthen our foundations

  • Unleashing the power of our people
  • Scaling data science and technology
  • Building trust with society

Related Content

Cover of the 2022 Novartis in Society Integrated Report, Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy

Novartis in Society Integrated Report 2022

The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.
Close up of a hand holding a lab sample

Innovative Medicines

Transformation to a pure-play innovative medicines company.
HCP discussing with patients in Africa

Environmental, Social and Governance

At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues.